JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level

Abstract: Natalizumab-treated patients have a higher risk of developing progressive multifocal leukoencephalopathy. Exposure to John Cunningham virus (JCV) is a prerequisite for PML (progressive multifocal leukoencephalopathy). To assess JCV exposure in multiple sclerosis patients, we performed a serological examination, obtained the antibody index, performed real-time polymerase chain reaction (PCR) to detect JCV DNA in plasma and urine, and investigated the role of ultrasensitive C-reactive protein (usCRP) as a possible biological marker of JCV reactivation. We retrospectively analyzed consecutive natalizumab-treated multiple sclerosis patients who underwent a JCV antibody test through a two-step enzyme-linked immunosorbent assay (STRATIFY test) to the measure of serum usCRP levels, and to perform blood and urine JCV PCR. The studied cohort included 97 relapsing–remitting patients (60 women). Fifty-two patients (53.6%) tested positive for anti-JCV antibodies. PCR showed JCV DNA in the urine of 30 out of 83 (36.1%) patients and 28 out of 44 seropositive patients (63.6%), with a 6.7% false-negative rate for the STRATIFY test. Normalized optical density values were higher in urinary JCV DNA-positive patients (P < 0.0001). Interestingly, the level of usCRP was higher in urinary JCV DNA-positive patients and correlated to the number of DNA copies in urine (P = 0.028). As expected, patients’ age correlated with JCV seropositivity and with JC viruria (P = 0.02 and P = 0.001, respectively). JC viruria was significantly correlated with a high JCV antibody index and high serum usCRP levels. We suggest that PCR and usCRP might be useful as markers of JCV reactivation, and that patients should be monitored between STRATIFY assessments.

Keywords: multiple sclerosis, John Cunningham virus, natalizumab, antibodies, polymerase chain reaction, ultrasensitive C-reactive protein

Introduction

Progressive multifocal leukoencephalopathy (PML) is a rare brain disease caused by the John Cunningham (JC) virus (JCV), a common polyomavirus.1 Primary infection by JCV usually occurs early in life, and the benign form of JCV remains asymptomatic in the kidneys throughout life.2,3 By means of complex interactions between the host and viral factors, JCV undergoes mutations in the regulatory region4 and in the coat protein of viral protein 1 (VP1).5 This causes a lytic infection of the brain’s oligodendrocytes, which represents the pathogenetic event that drives PML development.5 The reasons why some patients develop PML and most others do not may be related to different factors, such as rare bone marrow or other sites of viral latency, the effects of
drugs that immobilize specific progenitors into the periphery, host factors that predispose to viral replication, and trafficking of the virus into the brain where it may escape from a depleted or dysfunctional immune system. This serious rare disease generally occurs in severely immunocompromised individuals, especially in acquired immunodeficiency syndrome (AIDS) patients, as well as in some patients receiving immunosuppressive (mycophenolate mofetil) or biological (for example, efalizumab, natalizumab, alemtuzumab, and rituximab) therapies.7-5

Infection by JCV is a prerequisite for PML development and rates of seropositivity from 33%-91% have been previously reported.7-8-20 This discrepancy in rates was due to differences in sample size, demographics and, most importantly, assay methodologies.7-9-20

Recently, natalizumab was introduced in multiple sclerosis (MS) therapy. Its presumed mode of action is the inhibition of T-cell/monocyte entry into the brain, and the white cell count, which most prominently circulates B-cells and especially pre-B-cells, is increased in natalizumab-treated patients.21

Since PML cases developed while patients were on therapy with natalizumab, a two-step assay to detect anti-JCV antibodies in serum and plasma was established to provide a means to classify MS patients who have a detectable or nondetectable level of anti-JCV antibodies.22 The predictive value of this test was evident across 20 MS natalizumab-treated patients whose sera were available before PML development, with a positive result (seropositivity) in all of the samples.23 However, a 2.5% false-negative rate and seroconversion during therapy with natalizumab have been reported.22-24 Although this rate is considered low, it should be taken into account. Eventually, Berger et al25 affirmed that JCV antibody detection is an excellent tool for stratifying patients for PML risk, but that it underestimates infection rates.

Another way to monitor viral exposure in natalizumab-treated patients is via real-time polymerase chain reaction (PCR) to detect JCV DNA copies in patients’ fluids.26 Even if Rudick et al26 did not support JCV DNA testing in blood or urine samples with currently available PCR methodologies, because of its low sensitivity and low predictive value for PML, recently, Laroni et al27 re-evaluated urinary JCV DNA testing as a predictor of PML development and showed the presence of 5.5% false-negative JCV antibody tests in their population, reaffirming the role of PCR.

Since PCR is a time-intensive, expensive, and not an easily accessible technique, biological markers or predictors of JC reactivation would be highly necessary. Ultrasensitive C-reactive protein (usCRP) is considered a marker for unspecific inflammation, and it usually indicates a heightened state of inflammation in the body in response to many physical states, including fever, injury, and infection.28 Few studies report an increase of usCRP levels in AIDS patients on antiretroviral therapy, which is consistent with pre-existing subclinical tuberculosis, before the development of unmasking tuberculosis-associated immune reconstitution inflammatory syndrome.29 Moreover, CRP has gained increasing interest as a possible predictive marker of opportunistic infections in AIDS patients, and as a supportive marker of immunosuppression.30 In light of this evidence, the aim of our study was to assess, in our natalizumab-treated MS patient cohort, the correlation of the JCV antibody index with the occurrence of JCV DNA in the patients’ blood and urine (detected by PCR), and the role of usCRP as a possible biological marker of JCV reactivation.

Materials and methods
Patients
We designed an observational retrospective study that was conducted on all consecutive relapsing–remitting MS patients treated with natalizumab, or during the first natalizumab administration at the MS Center of Federico II University of Naples from March–October 2011.

Methods
All of the clinical assessments and analyses were performed as part of routine clinical practice. Demographic and clinical data were collected. Concomitant diseases were recorded. The number of natalizumab administrations and previous therapy exposure were registered.

Serological test
A serological test for anti-JCV antibodies configured as a two-step assay consisting of an enzyme-linked immunosorbent assay was performed in a centralized laboratory in Denmark (by United Laboratories, Mandaluyong City, Philippines) (STRATIFY test).22 The result of this test was a dichotomous (negative/positive) result. Only successive normalized optical density (nOD) (nOD450) values were used, and in the case of borderline results (nOD between 0.1 and 0.25), the percentage of inhibition during a confirmatory test was subsequently provided for scientific purposes. Patients who had negative results for the STRATIFY test, but positive results with PCR, were retested using a second-generation STRATIFY test.23
Real-time PCR

The presence of plasma or urinary JCV deoxyribonucleic acid (DNA) was used as a positive reference to determine false negative JCV antibodies patients.

The number of JCV DNA copies in plasma and urine samples was determined in 87 patients and 83 patients, respectively, using real-time PCR. For the isolation of viral DNA from 200 μL of urine and 200 μL of plasma samples, we used the Roche MagNA Pure LC Total Nucleic Acid Isolation Kit combined with the Roche MagNA Pure LC automated extractor (Hoffman-La Roche, Ltd, Basel, Switzerland). Blood samples were collected in sterile tubes with ethylenediaminetetraacetic acid K3 and centrifuged at 2,500 rpm/minute for 15 minutes. The plasma was separated from the corpuscular part, and when necessary, was stored at −20°C in sterile vials for molecular biology until analysis. Urine samples were stored under the same conditions as the plasma samples. The amount of JCV DNA was examined by real-time PCR using the LightCycler® 2.0 (Hoffman-La Roche Ltd). The primers and probes were supplied by TIB MOLBIOL GmbH (Berlin, Germany). Briefly, a 174 bp fragment of the JCV genome was amplified with specific primers and the amplification product was detected with fluorescence resonance energy transfer probes labeled with “LightCycler® Red 705”. The amplified product was identified by a melting curve with a specific melting temperature of 68°C and was read at 705 nm. A chain of DNA of 278 bp was added to the mixture, and this represented an internal control, which was amplified in the presence of negative or low viral loads and revealed by probes labeled with LightCycler® Red 705. The specific melting temperature of this control was 50°C, and amplification with its primers did not interfere with amplification of the target.

Biochemistry

Renal function laboratory tests (creatinine serum levels and proteinuria) and usCRP levels were performed at University Hospital “Federico II” DAsMeLab (Dipartimento Assistenziale di Medicina di Laboratorio).

Statistical analysis

Continuous normally distributed variables are shown as the mean ± standard deviation. Continuous, but not normally distributed variables, are shown as the median and range. Categorical data are reported as percentages and 95% confidence intervals (CIs). To compare continuous data, the unpaired Student’s t-test or the nonparametric Mann–Whitney U-test was used when appropriate. The Kruskal–Wallis test was used to compare more than two groups. For categorical data, the χ² test or Fisher’s exact test were used when appropriate. To assess the level of concordance, the value of Cohen’s k was calculated. We adopted the levels reported by Landis and Knoch. Receiver operating characteristic (ROC) curve analysis was performed, and the Youden’s index was used as possible threshold values for dividing patients into high-risk and low-risk groups regarding viral parameters. A P-value <0.05 was taken as statistically significant. Statistics was performed using MedCalc (MedCalc Software bvba, Ostend, Belgium).

Results

We included 97 relapsing–remitting MS patients (60 women) with a mean age of 38.2±11.2 years, a mean disease duration of 7±4 years, and a median number of natalizumab administrations of 17 (range: 0–41). No concomitant relevant diseases were present at the time of examination and renal function parameters were normal. The JCV antibody test was performed in all 97 patients, while PCR analysis of JCV DNA in urine samples was performed in 83 patients. Furthermore, the presence of JCV DNA in the blood was assessed in 89 patients of our cohort. Twenty-two patients (22.6%) were on natalizumab as the first therapy (naïve patients), 75 patients (77.3%) were on natalizumab as second-line therapy, and eleven patients (11.3%) had already used immunosuppressive drugs. The mean duration of previous therapies, including any treatment for MS, was 51±46 months.

In our cohort, the anti-JCV antibody prevalence was 53.6% (52 patients), with a median nOD value of 0.62 (range: 0.10–1.73). A confirmatory test was performed in 23 “borderline” patients, as defined in the “Materials and methods” section, and 13 patients were considered negative (inhibition test below 40%) while ten were positive for the presence of anti-JCV antibodies.

Real-time PCR showed the presence of urinary JCV DNA in 30 out of 83 (36.1%) examined patients (Figure 1) and plasma JCV DNA in one patient out of 89 (1.1%). Among the 44 seropositive patients tested for the presence of urinary JCV DNA, 28 (63.6%) showed positive results (Table 1). Two seronegative patients showed urinary JCV DNA copies (6.7% false-negative rate). The first patient was a 48-year-old man at his sixth infusion of natalizumab, with a nOD value of 0.101 and 35% inhibition, and he had presented with 300,000 JCV DNA copies/mL in his urine. Six months later, he was retested still using the first-generation STRATIFY test, and he again presented with a low antibody titer (nOD =0.107; inhibition: 34.8%), which was considered negative during a confirmatory test (nOD =0.093). Eventually, 1 year later,
he was tested with the second-generation STRATIFY test and the result was an indeterminate titer and a confirmatory test, which resulted in a negative result (index value not available). Furthermore, he showed fluctuating urinary JCV DNA levels over 2 years. The second patient was a 52-year-old woman at her 26th natalizumab infusion, with a nOD value of 0.093 and a constant presence of viral DNA for 28 months. The same patient was retested 1 year later using a first-generation STRATIFY assay and was considered positive with a nOD of 0.58. Therefore, excluding this patient that resulted seropositive at repetitive tests, the false-negative rate decreased to 3.3%. A unique patient (a 44-year-old woman) was positive for plasma JCV DNA and was seropositive, with a high nOD (=1.731) and 2,650,000 copies/mL of JCV DNA in her urine, at her 30th natalizumab administration. At repetitive tests, she was negative for JCV DNA in her plasma, and the copies of DNA in her urine were slightly decreased. She was discontinued from natalizumab, without any relevant complications.

In the entire cohort, the concordance rate between the presence of JCV antibodies and urinary JCV DNA was moderate ($k$=0.57). The sensitivity and specificity of the JCV antibody test were 93.3% (95% CI: 77.9%–99.2%) and 69.8% (95% CI: 55.7%–81.7%), respectively.

The nOD values were higher in urinary JCV DNA-positive patients than in negative ones ($P<0.0001$, Figure 2).

### Table 1 Clinical characteristics of the multiple sclerosis patients classified according the results of the presence of anti-JCV antibodies

<table>
<thead>
<tr>
<th>Patients</th>
<th>Anti-JCV antibodies, negative (n=45)</th>
<th>Anti-JCV antibodies, positive (n=52)</th>
<th>$P$</th>
<th>Statistical test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>35.37±1.48</td>
<td>40.59±10.50</td>
<td>0.021</td>
<td>Student’s t-test</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>18</td>
<td>19</td>
<td>0.57</td>
<td>$\chi^2$</td>
</tr>
<tr>
<td>Female</td>
<td>34</td>
<td>26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natalizumab administrations (n)</td>
<td>12 (0–41)</td>
<td>19 (0–40)</td>
<td>0.32</td>
<td>Mann–Whitney U-test</td>
</tr>
<tr>
<td>Previous therapies (months)</td>
<td>48 (0–148)</td>
<td>45 (0–146)</td>
<td>0.89</td>
<td>Mann–Whitney U-test</td>
</tr>
<tr>
<td>usCRP (mg/L)</td>
<td>0.80 (0.10–10.70)</td>
<td>0.95 (0.15–18.30)</td>
<td>0.41</td>
<td>Mann–Whitney U-test</td>
</tr>
<tr>
<td>Previous immunosuppressive drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>40</td>
<td>46</td>
<td>0.95</td>
<td>$\chi^2$</td>
</tr>
<tr>
<td>Yes</td>
<td>5</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JCV antibody test (nOD)</td>
<td>0.08 (0.06–0.16)</td>
<td>0.62 (0.10–1.73)</td>
<td>$&lt;0.0001$</td>
<td>Mann–Whitney U-test</td>
</tr>
<tr>
<td>Urinary JCV DNA (available only in 83 patients)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive (n=30)</td>
<td>2</td>
<td>28</td>
<td>$&lt;0.0001$</td>
<td>Fisher’s exact test</td>
</tr>
<tr>
<td>Negative (n=53)</td>
<td>37</td>
<td>16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** JCV, John Cunningham virus; n, number; usCRP, ultrasensitive C-reactive protein; nOD, normalized optical density; DNA, deoxyribonucleic acid.
but this was unrelated to the number of DNA copies. From the ROC analyses of urinary JCV DNA, the nOD threshold value to classify positive or negative patients was 0.197 (Figure 3).

Seropositivity was not related to any clinical parameters, the number of natalizumab administrations, or previous immunosuppressive therapies, but it was related to age ($P=0.021$). The presence of urinary JCV DNA was also only related to age ($P=0.001$; Table 2) and, interestingly, to serum usCRP levels ($P=0.028$; Figure 4). Serum usCRP levels were also correlated with the number of DNA copies in urine ($P=0.027$) and with age ($P<0.001$), but they were not correlated with any other demographic or clinical parameter (sex, disease duration, previous therapies, previous relapses, EDSS, and the number of natalizumab administrations). When patients were stratified for concomitant urinary JCV DNA and seropositivity or seronegativity (28 +/+, 2 +/−, 16 −/+ , 37 −/−), usCRP was not different among the groups ($P=0.063$). Renal function parameters and urinalysis results were not related to the presence of JCV DNA in urine samples.

**Discussion**

Risk stratification of PML in natalizumab-treated patients is a hot topic in the MS field. Use of the STRATIFY test to measure JCV exposure, despite its sensitivity, is still limited by the fact that no validated test exists to confirm true JCV exposure. A second-generation test with higher sensitivity was recently developed. Only recently, the antibody index for JCV has become available, showing some misinterpretation of results in the past, especially in the low titer range, leading to the perception that with binary positive/negative results there were some misinterpretations especially in the low titer range.

In this study, we measured the prevalence of JCV seropositivity with a first-generation STRATIFY test, with the related nOD values, and we correlated them to the presence of JCV DNA in blood and urine and to usCRP levels.

We found that the prevalence of JCV seropositivity was 53.6%, which is comparable with findings from larger studies and with data obtained from Italian patients. This prevalence was related to age, but not to sex, previous exposure to therapies, or the number of natalizumab administrations. The presence of JCV DNA in urine samples, which is considered as a sign of active proliferation of the virus, was found in 63.6% of our JCV seropositive patients and in 36.1% of the whole population, similar to previous data. We confirmed that shedding of the virus in biological fluids was not secondary to natalizumab treatment, because it was not related to the number of administrations, but it was related to age. Interestingly, the presence of JCV DNA in the urine was related to serum usCRP levels and to higher JCV antibody nOD values.

![Figure 3 ROC curve of the normalized anti-JCV level (nOD₄₅₀) values for the diagnosis of urinary JCV DNA.](image)

**Notes:** The area under the ROC curve was 0.903. The dotted lines represent the 95% confidence interval.

**Abbreviations:** OD, optical density; ROC, receiver operating characteristic; JCV, John Cunningham virus; nOD, normalized optical density; DNA, deoxyribonucleic acid.
JCV DNA presence in the blood has never been clearly related to PML development, while there are some favorable reports of JCV DNA presence in urine as a risk factor for developing PML, as already cited (Rudick et al26 and Laroni et al27). To the best of our knowledge, there are no correlations of JCV DNA in the blood or urine with cerebrospinal fluid viral presence (not constant in PML patients) and to PML disease activity.

An increase in JCV viruria with age, consequent to a reactivation of the retained latent kidney’s viruses is a well-known phenomenon,16,36 while its association with usCRP levels is a completely new finding that might open a novel prospective in the field. Nevertheless, we must consider that usCRP is an unspecific test, which might be increased as a consequence of an inflammatory state; however, in our patients, no concomitant diseases related to an inflammatory state were recorded. Therefore, its role as a marker of urinary shedding of the JC virus, secondary to its reactivation, is a very appealing hypothesis.

Moreover, we found a false-negative rate of 6.7, which is higher than the rate originally described.22 When we examined the two seronegative patients with JCV viruria in detail, we found that the first patient (a man with persistent negative values) was a false-negative patient with a constantly low immune response to JCV and a low viral load, while the second patient had fluctuating antibody levels over time, leading to a false-negative result at the first test. Therefore, the false-negative rate decreased to 3.3% with repetitive tests, as described in the literature.22

However, calculation of a false-negative rate, and the sensitivity and specificity of the anti-JCV antibody test used in this study, was greatly limited by the size of the cohort. Moreover, when using JC viruria to validate exposure data, repetitive sampling in the same individuals would add important information because excretion in urine occurs intermittently.

**Conclusion**

In conclusion, in our study, the two methodologies used to determine JCV exposure in natalizumab-treated patients showed a comparable prevalence of viral contact and active replication with that described in the literature in other populations.27,34,35 However, such methodologies shared a modest concordance ($k=0.57$), with 63.6% of seropositive patients showing an active viral replication. This is an
expected discrepancy in a transversal study design, due to the intermittent excretion in urine of JCV DNA. Therefore, because of the relevant usefulness of the anti-JCV antibody assays as a tool for stratifying MS patients into higher or lower risk for PML development, PCR might be an additional useful approach to test viral reactivation and load. Additionally, during natalizumab therapy, in the interval between performing two STRATIFY tests, PCR can provide evidence for a patient’s first exposure to JCV. Together with usCRP levels, PCR might represent a useful tool to follow up with JCV seropositive patients, to increase their surveillance, and to determine whether active viral replication is ongoing. Eventually, the recent availability of the JCV antibody index through a second-generation STRATIFY test will help when making therapeutic decisions, avoiding false-negative results. Although these are appealing possibilities, they need confirmation through larger and longitudinal studies.

Acknowledgments
We are grateful to Biogen Idec for providing the JCV antibody test facilities and Unilabs for kindly providing nOD values.

Disclosure
Roberta Lanzillo has received honoraria from Bayer Shering, Biogen Idec, Merck-Serono, TEVA, and Novartis for giving lectures or being on scientific boards. Giovanni Vacca has received honoraria from Bayer Shering for consultancy. Vincenzo Brescia Morra has received honoraria from Bayer Shering, Biogen Idec, Merck-Serono, TEVA, Aventis, and Novartis for giving lectures or being on scientific boards. Raffaele Liuzzi, Luca Vallesuoco, Luca Amato, Veria Vaccchian, Marcello Moccia, and Giuseppe Portella report no conflicts of interest in this work.

References